Heart failure & cardiomyopathiesSecondary analysis
Efficacy of Aficamten vs Metoprolol According to Pretrial Beta-Blocker Treatment in Obstructive Hypertrophic Cardiomyopathy
- Secondary analysis of the MAPLE-HCM randomised trial
Authors' conclusion
Aficamten was superior to metoprolol regardless of BB use at screening or prior SOC medications.
Study context
- Population
- Obstructive hypertrophic cardiomyopathy (oHCM)52 BB-no, 123 BB-yes, 22 standard-of-care (SOC)-no
- Participants
- 175 participants
- Comparison
- Aficamten vs metoprolol, by pretrial beta-blocker or SOC therapy
Primary result
As reported in the abstract
Peak oxygen uptake, by pretrial therapy subgroup
- BB-no
- difference +3.1 mL/kg/min (95% CI 1.8–4.5); P < 0.001
- BB-yes
- difference +1.9 mL/kg/min (95% CI 0.9–2.8); P < 0.001
- SOC-no (all also in BB-no)
- difference +4.1 mL/kg/min (95% CI 2.2–6.0); P < 0.001
Further findings
Multiple efficacy endpoints
- Consistent benefits of aficamten vs metoprolol, independent of pretrial medical therapy
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Efficacy of Aficamten vs Metoprolol According to Pretrial Beta-Blocker Treatment in Obstructive Hypertrophic Cardiomyopathy. JACC Heart Fail. Published 29 August 2026. doi:10.1016/j.jchf.2026.103352
Summarised from the published abstract; every number is checked against it